Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Morphotek, a subsidiary of Eisai Corporation of North America, has signed a license agreement with the National Cancer Institute for the rights to a monoclonal antibody for a novel antigen identified by the National Cancer Institute researchers.
Subscribe to our email newsletter
Morphotek said that it will apply its proprietary Morphodoma antibody technology to the development of novel human therapeutic antibodies for use in the treatment of prostate cancer.
This is the second agreement signed in 2008 between the National Cancer Institute and Morphotek to expand their efforts in developing new therapies for the treatment of prostate cancer.
Nicholas Nicolaides, president and CEO of Morphotek, said: “This agreement represents another important milestone in our efforts to expand our antibody portfolio. We remain committed to advancing monoclonal antibody therapies for clinical development in this therapeutic area, which if promising, may one day become available to patients with prostate cancer.”